Leerink Partners Remains Bullish as Alere (ALR) Withdraws INRatio and INRatio 2 Products
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Alere to Initiate Voluntary Withdrawal of the Alere INRatio® and INRatio®2 PT/INR Monitoring System
July 11, 2016 5:00 PM EDTWALTHAM, Mass., July 11, 2016 /PRNewswire/ -- Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. (NYSE: ALR) will be initiating a voluntary withdrawal of the Alere INRatio® and INRatio®2 PT/INR Monitoring System. Alere is working with the FDA to determine the most appropriate timing for product discontinuation and will provide guidance on transitioning patients to an alternate solution to allow them to continue anti-coagulation monitoring in the least disruptive manner possible.
Alere's focus, as always, is on the safety of patients using the company's... More
